EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Comparative assessment of the cost-effectiveness of two molecular biological test systems for CT/NG detection using time-driven activity-based costing

Bei-Jia Yu, Wenjie Lu, Meiqin Shi, Ting-Ting Jiang, Ling Guo, Fei Liu, Yan Han, Yue-ping Yin, Ksenia Plakhova, Xiang-Sheng Chen

Vestnik dermatologii i venerologii · 2026-10-09 · 102 (4) · 68-82

DOI: 10.25208/vdv17020 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND: Nucleic Acid Amplification Tests (NAAT) are the primary test method for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections, among which GeneXpert® CT/NG assay and сobas® 4800 CT/NG test (Roche, Switzerland) are widely used. However, the comprehensive cost-effectiveness of these two methods remains a key factor in the decision-making of healthcare institutions. AIM: To compare the full-process costs of the GeneXpert® CT/NG assay and the cobas® 4800 CT/NG test under different instrument configurations and daily testing volumes, so as to provide a basis for healthcare institutions to select appropriate testing options. METHODS: A Time-Driven Activity-Based Costing (TDABC) model was developed, categorizing costs into labor, instrument depreciation and maintenance, consumables, space, and electricity. Cost formulas were derived for different instrument configurations under varying daily testing volumes (n). RESULTS: Cost analysis showed that when the daily testing volume (n) is ≤10, the total cost of the 2 or 4 channel Xpert® system is lower than that of the cobas® 24. For the cobas® 96 system, the Xpert® 16, 48, and 80 channel systems have a cost advantage when n ≤ 34, n ≤ 26, and n ≤ 23, respectively. Reagents and consumables constitute the largest proportion of total costs. In addition, the Xpert® system can complete up to five batches per day, whereas the cobas® 24 and 96 complete a maximum of four and three batches per day respectively, offering faster turnaround time for individual samples. CONCLUSION: For institutions with a daily testing volume below 10 samples, the Xpert® 2 or 4 channel model is recommended for optimal cost-efficiency and reduced patient waiting time. For high-throughput settings (e. g. 100 samples/day), the cobas® 96 or higher channel Xpert® models (48/80) are suitable alternatives. The choice should be guided by the actual daily testing volume, workflow, and resource constraints.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →